Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing the consent form
- People who have been diagnosed with an advanced or spreading solid tumour (confirmed by lab testing of tumour tissue) that cannot be removed by surgery and has not responded to standard treatments, or people who have a lymphoma that has come back or stopped responding to treatment
- People whose tumour has a specific molecular change called MTAP deficiency, confirmed by laboratory testing
- People who have at least one tumour that can be detected and assessed on scans at the start of the study
- People whose general health and ability to carry out daily activities meets a specific standard (rated 0 or 1 on a medical scale, meaning fully active or able to carry out light activity)
- People whose blood counts, heart, liver, kidney, and clotting functions are within acceptable ranges based on lab tests
Who may not be able to join:
- People who are pregnant or breastfeeding
- People who have difficulty swallowing or have a condition that seriously affects how the gut absorbs medications
- People who have a known allergy or intolerance to any ingredient in the study drug
- People who have received any anti-cancer treatment within 28 days before the study start date
- People who have previously been treated with a MAT2A inhibitor or a PRMT5 inhibitor (specific types of cancer drugs) (confirm with trial site)
- People who have cancer that has spread to the brain or spinal cord at the time of screening
- People who have received a live vaccine within 4 weeks before starting the study drug
- People who are using prescription blood-thinning medications to treat an active blood clot condition
- People who have taken certain prescription medications known to strongly affect how the body processes drugs (strong CYP3A4 inducers or inhibitors) within 14 days or 5 half-lives before the study start date, whichever is longer
- People who still have unresolved side effects from previous cancer treatments
- People with an active HIV, hepatitis B, or hepatitis C infection
- People whom the study doctor considers unsuitable for the trial due to other serious health conditions or any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Haiping Wu, PhD, CytosinLab Therapeutics Co., Ltd.
Phone: 0086-21-58920766
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase I: Number of Patients Who Experience a Dose-Limiting Toxicity (DLT); Phase I: Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE); Phase II: Objective Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.